Joyce University Expands Nursing Education to Michigan Students
SALT LAKE CITY--(BUSINESS WIRE)--Aspiring nurses in Michigan can now prepare for RN licensure in as few as 20 months. Joyce University of Nursing and Health Sciences is broadening its hybrid pre- and post-licensure nursing programs into Michigan.
Over the last three years, Joyce University has steadily expanded beyond Utah, now serving students in 14 states, including its latest additions in 2025: Michigan and Kentucky. This growth reflects the university's commitment to providing flexible, career-focused educational pathways to meet the increasing demands for skilled nurses throughout Michigan.
With this expansion, students in Michigan can access a range of pre-licensure programs, such as the 20-month Associate of Science in Nursing (ASN), the 3-year Bachelor of Science in Nursing (BSN), and the accelerated Bachelor of Science in Nursing (aBSN). Joyce University offers two post-licensure programs for those looking to further their nursing careers: the 4-semester online RN to BSN program and the 3-semester online MSN in Leadership program.
Students benefit from a hybrid approach, attending online lectures while gaining hands-on experience at the Joyce Johnson Center of Simulation in Draper, Utah. To minimize travel and foster local connections, clinical experiences take place in each student's state of residence.
Enrollment for Michigan students is now open, with the next cohort starting in the Fall Semester on September 2nd.
For more information about Joyce University programs or employment opportunities, visit joyce.edu.
ABOUT JOYCE UNIVERSITY
Founded in 1979, Joyce University of Nursing and Health Sciences ' mission is to prepare students to serve as competent professionals, to advance their careers, and to pursue lifelong learning. Located in Draper, Utah, Joyce University is proud to have helped thousands of students across the US graduate and launch lasting healthcare careers. With a recent expansion of its pre-licensure programs to select regional locations, including Arizona, Colorado, Idaho, Kentucky, Michigan, Missouri, Nevada, New Mexico, Ohio, Oregon, South Carolina, and Wisconsin. Joyce University's expansion enables aspiring nurses in these regions to access the same high-quality education and opportunities that have defined the institution for decades. Join them as they continue to shape the future of healthcare, one student at a time.
Joyce University is institutionally accredited by the Northwest Commission on Colleges and Universities (NWCCU) and programmatically accredited by the Accreditation Commission for Education in Nursing (ACEN) for the Associate of Science in Nursing degree program and by the Commission on Collegiate Nursing Education (CCNE) for the Bachelor of Science in Nursing and Master of Science in Nursing degree programs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
14 hours ago
- Business Wire
GE HealthCare drives innovation in theranostics with latest technological advances
CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.
Yahoo
15 hours ago
- Yahoo
Port Glasgow nurse says she's been ‘blown away' by the work of Ardgowan Hospice
AN INSPIRATIONAL Port Glasgow nurse who has been caring for people for more than 30 years has brought her career back to Inverclyde help people receiving palliative care. Pauline McIntyre is director of patient and family services at Ardgowan Hospice, and says stepping into the role last year was made 'all the more special' by being able to help the people of Inverclyde - where she began her career. The 54-year-old told the Tele that she knew nursing was the career for her from as early as 17. She left school to become a pre-nursing student at the former Ravenscraig Hospital, knowing she wanted to have a job that would help people, such as healthcare or policing. She was inspired by her grandparents who both served in the armed forces. Pauline McIntyre joined Ardgowan Hospice in 2024 as the Director of Patient and Family Service (Image: George Munro) Throughout her nursing career, Pauline has worked in acute rehabilitation in Bridge of Weir, helped set up the Larkfield stroke unit at Inverclyde Royal Hospital, and then took up the position of practice development nurse manager at Erskine Hospital, being drawn to working in the veterans' home through the personal connection. After working in a variety of roles, including teaching and healthcare governance, Pauline brought her skills back home to the hospice in 2024. Pauline told the Tele: 'Throughout my career, I have been privileged to work with people who are absolutely caring right down to their core and do their very best for people. 'I have been blessed to have these experiences and worked alongside such amazing teams. Everyone [at Ardgowan Hospice] is absolutely that. 'I have always tried to enhance my career. I have never stood still. The saying 'every day is a learning day' is true, because after all of these years I am still learning new ways to bring the best care to people. "The hospice has already taught me so much." Other News Inverclyde's Best Home: Steampunk-inspired flat is a hidden Greenock gem Fury as mindless vandals target passenger shelter at Greenock station Greenock's Clyde Tool Hire answer appeal from BBC show DIY SOS Pauline says she was 'blown away' with the collaborative work that all of the teams within the hospice do, from the transport team to the kitchen staff and the community nurses. She added: 'Palliative care has always been a passion of mine from day one. No matter what setting you work in, [palliative care] is always involved. 'It feels special to be back working [in Inverclyde]. 'It is my community, and it is where I was raised and went to school and completed my training. 'I always remember my nurse lecturer saying to me to 'go and explore the field but bring back your skills', and I feel like that is what I have done.' When Covid struck, Pauline used her skills on a national level, working alongside pharmacists to develop policies on the repurposing of medicines, as well as helping to rewrite infection prevention and control standards. Pauline says being involved with nursing throughout the pandemic and on a national level inspired her to become more involved with end-of-life care. The 54-year-old, who achieved her Queen's Nurse award in 2019, says she will 'never forget her roots' from her days working on the hospice - and says she enjoys being able to interact with the patients at the Nelson Street hospice. MORE FROM ARDGOWAN HOSPICE: PICTURES: Thousands raised for Ardgowan Hospice at annual Ladies' Day event Dedicated hospice volunteer urges others to take 'tremendously rewarding' role Ardgowan Hospice calls for community to support online fundraising efforts 'Women have cried': Straps in Gourock on the difference a well-fitted bra can make Brave Greenock woman who lives with health conditions walks miles for charity "Not everybody knows what the hospice is all about," she said. "I certainly didn't know it all, and I have lived here all my days. 'Coming in during my first weeks, and seeing such an age variety, was something not a lot of people think of in a hospice. 'That's because cancer or life-limiting illness touches every age. "You have to adapt and work in a person-centred way to make sure that person's wishes and care is fulfilled. "That's what everybody in Ardgowan Hospice strives to do, no matter what position they work in. 'This service is for the people of Inverclyde. It's theirs, and without the donations and support we get from the community we wouldn't be able to do what we do and help so many people.'
Business Wire
a day ago
- Business Wire
CCS Presents Four Peer-Reviewed Posters at American Diabetes Association's 85th Scientific Sessions
CHICAGO--(BUSINESS WIRE)-- CCS, a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, will present four peer-reviewed posters at the American Diabetes Association's (ADA) 85th Scientific Sessions, which will take place June 20–23 in Chicago. These latest poster presentations illustrate CCS's focus on delivering evidence-based approaches to diabetes care management that ensure patients have the education and coaching they need to thrive and cost-effectively stay adherent while managing their chronic condition. "At CCS, we meet patients where they are — with empathy, education, and evidence-based support..." Share The ADA Scientific Sessions is a globally recognized conference dedicated to advancing the field of diabetes. This annual meeting serves as a critical forum for presenting cutting-edge research, innovation, and new evidence-based approaches to diabetes prevention, management, and care. Presentation Highlights from CCS at the ADA Scientific Sessions CCS's clinical strategy and innovation vice president, Coni Dennis, DNP, RN, and NE-BC, will present findings for all four accepted poster presentations at the ADA's 85th Scientific Sessions, and she shared this insight leading into the event: 'At CCS, we meet patients where they are — with empathy, education, and evidence-based support. These poster presentations reflect our commitment to improving health outcomes for people with diabetes by combining data-driven clinical insight with hands-on, compassionate care.' All poster presentations will take place at the conference on Sunday, June 22, from 12:30–1:30 p.m. CT in West Hall F1. The following are the four specific posters that CCS will be presenting: Presentation Title: Evaluating the Impact of Multichannel Diabetes Care Coaching and Education in Patients New to Continuous Glucose Monitoring Abstract Number: 534 Summary: This study, part of an ongoing randomized control trial (RCT), evaluated whether adults with diabetes newly starting a continuous glucose monitor (CGM) achieve better outcomes when they receive diabetes self-management education and support (DSMES) from a certified diabetes care and education specialist (CDCES), compared to using a CGM alone. Presentation Title: Examining the Impact of Continuous Glucose Monitoring Sourcing in Medicaid Patients — Adherence, Healthcare Costs, and Utilization Abstract Number: 1046 Summary: This study compared healthcare costs and utilization among Medicaid beneficiaries who received CGM supplies through a pharmacy or a durable medical equipment provider. Presentation Title: Healthcare Costs and Utilization Among Patients Eligible for Continuous Glucose Monitors — A Comparison of Users and Nonusers Abstract Number: 1049 Summary: This retrospective cohort study used claims data to compare glycemic control, healthcare utilization, and total cost of care over 12 months among individuals on bolus insulin who used CGMs versus those who did not. It also assessed the incidence of hypoglycemia and diabetic ketoacidosis (DKA). Presentation Title: Evaluating an Evidence-Based Quality Improvement Initiative for Food Insecurity Screening and Referral in Adults with Diabetes Initiating Continuous Glucose Monitor Therapy Abstract Number: 1143 Summary: This study assessed food insecurity (FI) among adults with diabetes initiating CGM therapy, comparing rates to national averages and examining glycemic outcomes between food-insecure and food-secure individuals. These posters will be made available on the American Diabetes Association's website after August 25. About CCS CCS is the strategic partner addressing America's most pressing healthcare challenges through intelligent chronic care management, tackling the $412 billion annual diabetes burden and chronic conditions affecting over 133 million Americans. At the core of CCS's differentiated model is LivingConnected®, a human-led, digitally enabled clinical solution. PropheSee™ — an AI-powered predictive model that identifies nonadherence risk and delivers personalized interventions — is an integral part of this solution, creating a first-of-its-kind platform to improve adherence, enhance clinical outcomes, and help prevent costly hospitalizations. By combining data-driven insights with three decades of industry relationships, CCS is the smart choice for health plans, providers, employers, and manufacturers who believe that value-based care starts by keeping patients healthy and delivers benefits like lower cost of care, improved HEDIS scores, and alleviating provider burnout. CCS's approach extends clinical reach while supporting over 200,000 people nationwide with home-delivered medical supplies and pharmaceuticals annually. Recognized as a Great Place to Work® and with numerous peer-reviewed publications validating our care management approach, CCS is more than a trusted supplier — we're a partner in transforming chronic care delivery. To learn more about how CCS is addressing today's healthcare challenges, visit or connect with us on LinkedIn.
